机译:解雇RNA聚合酶II是大型配体诱导的增强剂退役计划
Howard Hughes Medical Institute Department of Medicine University of California;
Howard Hughes Medical Institute Department of Medicine University of California;
Howard Hughes Medical Institute Department of Medicine University of California;
Howard Hughes Medical Institute Department of Medicine University of California;
Stanford University School of Medicine;
Howard Hughes Medical Institute Department of Medicine University of California;
Howard Hughes Medical Institute Department of Medicine University of California;
Howard Hughes Medical Institute Department of Medicine University of California;
Howard Hughes Medical Institute Department of Medicine University of California;
Howard Hughes Medical Institute Department of Medicine University of California;
Howard Hughes Medical Institute Department of Medicine University of California;
Howard Hughes Medical Institute Department of Medicine University of California;
Department of Structural and Chemical Biology Mount Sinai School of Medicine;
Howard Hughes Medical Institute Department of Medicine University of California;
ERα; enhancer; KDM2A; NEDD4; Pol II; transcription; decommission; eRNA; nuclear receptor; repression;
机译:解雇RNA聚合酶II是大型配体诱导的增强剂退役计划
机译:RNA聚合酶III启动子元件增强RNA聚合酶II基因的转录
机译:HDAC抑制剂增强RNA聚合酶III启动子驱动的IDO shRNA的癌症治疗效率
机译:通过RNA聚合酶I,II和III的转录C-MYC激活
机译:RNA聚合酶II在很长的距离内增强子作用并通过核小体转录的机制。
机译:RNA聚合酶II的解雇是大型配体诱导的增强子退役计划的基础
机译:RNA聚合酶II的外源性积累增强了RNA聚合酶III的转录。